D. Stokesberry

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Fraser Cummings, S. Vermeire, E. Savarino, 2022, The Lancet.

Direct determination of the point mutation rate of a murine retrovirus

L. Evans, F. Malik, D. Stokesberry, 1992, Journal of virology.

Direct Determination ofthePointMutation Rate ofa MurineRetrovirus

D. Stokesberry, 1992 .

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.

A. Gasbarrini, B. Sands, I. Lawrance, 2023, Gastroenterology.